Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38185   clinical trials with a EudraCT protocol, of which   6272   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-003489-42
    Sponsor's Protocol Code Number:31-12-294
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2013-02-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-003489-42
    A.3Full title of the trial
    An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette?s Disorder
    Estudio clínico multicéntrico, abierto para evaluar la seguridad y la tolerabilidad del aripiprazol administrado por vía oral una vez al día a niños y adolescentes con el síndrome de Gilles de la Tourette.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette?s Disorder
    Ensayo clínico para evaluar la seguridad del del aripiprazol en niños y adolescentes con el síndrome de Gilles de la Tourette.
    A.4.1Sponsor's protocol code number31-12-294
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportOtsuka Pharmaceutical Development & Commercialization, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOtsuka Pharmaceutical Development & Commercialization, Inc.
    B.5.2Functional name of contact pointEva Kohegyi
    B.5.3 Address:
    B.5.3.1Street Address2440 Research Boulevard
    B.5.3.2Town/ cityRockville, Maryland
    B.5.3.3Post code20850
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 6095246790
    B.5.5Fax number+1 240 5143890
    B.5.6E-mailEva.Kohegyi@otsuka-us.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abilify
    D.2.1.1.2Name of the Marketing Authorisation holderOtsuka Pharmaceutical Europe
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAripiprazole
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNARIPIPRAZOLE
    D.3.9.1CAS number 129722-12-9
    D.3.9.4EV Substance CodeSUB05564MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abilify
    D.2.1.1.2Name of the Marketing Authorisation holderOtsuka Pharmaceutical Europe
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAripiprazole
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNARIPIPRAZOLE
    D.3.9.1CAS number 129722-12-9
    D.3.9.4EV Substance CodeSUB05564MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abilify
    D.2.1.1.2Name of the Marketing Authorisation holderOtsuka Pharmaceutical Commercialization & Development, Inc.
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAripiprazole
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNARIPIPRAZOLE
    D.3.9.1CAS number 129722-12-9
    D.3.9.4EV Substance CodeSUB05564MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abilify
    D.2.1.1.2Name of the Marketing Authorisation holderOtsuka Pharmaceutical Europe
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAripiprazole
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNARIPIPRAZOLE
    D.3.9.1CAS number 129722-12-9
    D.3.9.4EV Substance CodeSUB05564MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Tics associated with Tourette?s Disorder in children and adolescents
    Tics asociados al Síndrome de Gilles de la Tourette en niños y adolescentes
    E.1.1.1Medical condition in easily understood language
    Sudden, repetitive and involuntary physical movements and vocal utterances associated with Tourette?s Disorder
    Movimientos físicos y expresiones vocales repentinos, repetitivos e involuntarios y asociados al Síndrome de Gilles de la Tourette
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Mental Disorders [F03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10044126
    E.1.2Term Tourette's disorder
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the long-term safety and tolerability of aripiprazole once-daily treatment with oral tablets in children and adolescents (7 -17 years of age) with a diagnosis of Tourette?s Disorder
    Evaluar la seguridad y tolerabilidad a largo plazo del tratamiento con comprimidos de aripiprazol administrados por vía oral una vez al día a niños y adolescentes (de 7 a -17 años de edad) con diagnóstico de síndrome de Gilles de la Tourette
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of once-daily aripiprazole in the suppression of tics in children and adolescents with a diagnosis of Tourette?s Disorder, as measured by change from Baseline to endpoint on the TTS of the YGTSS
    Evaluar la eficacia del aripiprazol administrado una vez al día para la supresión de tics en niños y adolescentes con un diagnóstico de síndrome de Gilles de la Tourette, determinada por los cambios producidos desde los valores iniciales hasta los valores finales en la puntuación total de tics (TTS, por sus siglas en inglés) de la escala global de Yale sobre gravedad de los tics (YGTSS)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent must be obtained from a legally acceptable representative (eg, guardian or caregiver), in accordance with requirements of the trial center?s IRB/IEC, prior to the initiation of any protocol-required procedures. In addition, the subject, as required by the trial center?s IRB/IEC, must provide informed assent at Baseline and as such must be able to understand that he or she can withdraw from the trial at any time.
    2. The subject and the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.
    3. The subject completed Trial 31-12-293. Subjects who completed the Week 8 visit of Trial 31-12-293 are defined as trial completers.
    1)Se debe obtener el consentimiento informado por escrito de un representante legalmente autorizado (p. ej., un tutor o una persona designada para cuidar del paciente ), de conformidad con los requisitos del IRB/CEI del centro del estudio clínico, antes de iniciar cualquier procedimiento requerido por el protocolo. Además, el paciente, según lo requieran el IRB/CEI del centro del estudio clínico, debe proporcionar un asentimiento informado en la selección y debe comprender que puede retirarse del estudio clínico en cualquier momento.
    2)El paciente y los tutores designados o las personas designadas para cuidar del paciente deben poder comprender y cumplir satisfactoriamente con los requisitos del protocolo, según la opinión del investigador.
    3)El paciente ha completado el estudio 31-12-293. Los pacientes que completen la visita de la semana 8 del estudio 31-12-293 se definen como pacientes que han completado el estudio.
    E.4Principal exclusion criteria
    1. The subject experienced AEs during the double-blind trial that would, in the investigator's judgment, preclude further exposure to aripiprazole.
    2. The subject had protocol violations during the double-blind trial considered major in the judgment of the investigator (significant noncompliance, use of prohibited concomitant medications, concern with use of drugs of abuse, etc.), which would deem them poor candidates for this trial.
    3. A positive drug screen at Baseline (ie, Day 0/last visit of double-blind trial, Protocol 31-12-293) for cocaine, alcohol, or other drugs of abuse (excluding caffeine, nicotine, or prescribed psychostimulants for ADD/ADHD) which will result in early termination on Week 1.
    4. Sexually active males who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 90 days following the last dose of study drug, or sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 30 days following the last dose of study drug. Abstinence will be permitted if it is confirmed and documented at every trial visit. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injections, implant, condom, or sponge with spermicide.
    5. Females who have a positive urine pregnancy test result prior to receiving trial drug, or are pregnant or lactating.
    6. The subject represents a significant risk of committing suicide based on a routine psychiatric status examination, investigator?s judgment or who have an answer of ?yes? on any question other than 1-3 on the C-SSRS.
    7. Body weight is lower than 16 kg.
    8. The following vital signs and ECG results are exclusionary:
    1) Diastolic blood pressure > 105 mmHg
    2) QTc ? 450 msec on either the QTcB (Bazett?s) or QTcF (Fridericia) corrections on 2 of 3 time points (see NOTE below)

    The following laboratory test results will result in discontinuation at the Week 1 visit:
    1) Platelets ? 75,000/mm3
    2) Hemoglobin ? 9 g/dL
    3) Neutrophils, absolute ? 1000/mm3
    4) Aspartate aminotransferase (AST) > 3 x ULN as defined by the central laboratory
    5) Alanine aminotransferase (ALT) > 3 x ULN as defined by the central laboratory
    6) Creatinine ? 2 mg/dL
    NOTE: In addition, subjects should be excluded (or discontinued at the Week 1 visit for abnormal laboratory tests) if they have any other vital sign results or ECG findings which in the investigator?s judgment are medically significant and would impact the safety of the subject or the interpretation of the trial results. Criteria are provided in the protocol to assist investigators in their assessments of results that may be potentially medically significant, depending on the subject?s medical history and clinical presentation.
    1)El paciente presentó AA durante el estudio clínico previo que, según criterio del investigador, impiden la exposición posterior al aripiprazol.
    2)El paciente cometió violaciones del protocolo durante el estudio clínico anterior consideradas importantes según el criterio del investigador (incumplimiento significativo, uso de medicamentos concomitantes prohibidos, dudas respecto del uso de drogas ilegales, etc.), lo que lo habría clasificado como un mal candidato para este estudio clínico.
    3)Un resultado positivo en la prueba de detección de drogas en la visita inicial (es decir, el día 0/la última visita del estudio clínico anterior) para cocaína, alcohol u otras drogas ilegales (quedan excluidas la cafeína, la nicotina o los psicoestimulantes recetados para el TDA/TDAH) resultará en la finalización prematura en la visita de la semana 1.
    4)Los varones sexualmente activos que no se comprometan a utilizar 2 de los métodos anticonceptivos aprobados o que no practiquen la abstinencia sexual durante el estudio clínico y los 90 días posteriores a la última dosis del medicamento del estudio clínico, ni las mujeres sexualmente activas con capacidad para procrear que no se comprometan a utilizar 2 métodos anticonceptivos aprobados o que no practiquen la abstinencia sexual durante el estudio clínico y los 30 días posteriores a la última dosis del medicamento del estudio clínico. Se permitirá la abstinencia sexual si se confirma y documenta en cada una de las visitas del estudio clínico. Si se emplean métodos anticonceptivos, se deben tomar 2 de las siguientes precauciones: vasectomía, ligadura de trompas, diafragma vaginal, dispositivo intrauterino, píldora anticonceptiva, inyecciones anticonceptivas de liberación lenta, implante, preservativo o esponja con espermicida.
    5)Las mujeres que obtengan un resultado positivo en una prueba de embarazo en orina antes de recibir el medicamento del estudio clínico, o que estén embarazadas o en periodo de lactancia materna.
    6)El paciente que representa un riesgo importante de cometer suicidio en función del examen rutinario del estado psiquiátrico, según criterio del investigador, o aquel que ha respondido afirmativamente a cualquiera de las preguntas que no sean de la 1 a la 3 de la escala C-SSRS.
    7)Los pacientes con un peso corporal inferior a 16 kg.
    8)Los siguientes resultados de las constantes vitales y los ECG son excluyentes:
    1)Presión arterial diastólica > 105 mmHg.
    2)QTc ? 450 mseg en las correcciones de los intervalos QTcB (fórmula de Bazett) o de QTcF (fórmula de Fridericia) en 2 de los 3 momentos de determinación (consulte la NOTA que se incluye a continuación).

    Los siguientes resultados de los análisis clínicos resultarán en la suspensión de la participación en la visita de la semana 1:
    1)Plaquetas ? 75.000/mm3.
    2)Hemoglobina ? 9 g/dl.
    3)Neutrófilos, valor absoluto ? 1000/mm3.
    4)Aspartato aminotransferasa (AST) > 3 veces el límite superior de lo normal (LSN) según lo definido por el laboratorio central.
    5)Alanina aminotransferasa (ALT) > 3 veces el LSN según lo definido por el laboratorio central.
    6)Creatinina ? 2 mg/dl.

    NOTA: además, se deben excluir los pacientes (o suspender su participación en la visita de la semana 1 de análisis clínicos anormales) ante cualquier otro resultado en las constantes vitales o hallazgos en el ECG que según criterio del investigador sean importantes desde el punto de vista médico y que podrían afectar a la seguridad del paciente o a la interpretación de los resultados del estudio clínico. Los criterios se proporcionan para ayudar a los investigadores en las evaluaciones de resultados que, posiblemente, sean importantes desde el punto de vista médico, según los antecedentes médicos y la presentación clínica del paciente.
    E.5 End points
    E.5.1Primary end point(s)
    Safety, including the following:
    -AEs
    -Laboratory tests (haematology, serum chemistry [including prolactin
    and thyroid stimulating hormone (TSH)], urinalysis, and pregnancy
    tests)
    -Vital signs
    -ECGs
    -AIMS and other EPS scales
    -C-SSRS
    -ADD/ADHD Subscale of SNAP-IV
    -CY-BOCS
    -CDRS-R
    -PARS
    -Body weight
    -Waist circumference
    -Body mass index (BMI)
    Seguridad:
    -AA.
    -Análisis clínicos (hematología, bioquímica sérica [que incluye prolactina y tirotropina (TSH)], análisis de orina y pruebas de embarazo).
    -Constantes vitales.
    -Electrocardiogramas.
    -Escala AIMS y otras escalas de SEP.
    -Escaña C-SSRS.
    -SNAP-IV.
    -Escala CY-BOCS.
    -Escala CDRS-R.
    -Escala PARS.
    -Peso corporal.
    -Perímetro de la cintura.
    -Índice de masa corporal (IMC
    E.5.1.1Timepoint(s) of evaluation of this end point
    52 weeks
    52 semanas
    E.5.2Secondary end point(s)
    -Change from Baseline to endpoint in YGTSS TTS
    -Mean CGI-TS change score at endpoint (change score obtained from
    CGI-TS improvement scale assessment)
    -Change from Baseline to endpoint in CGI-TS severity score
    -Mean change from Baseline to endpoint in Total YGTSS score
    -Response rates (clinical response will be defined as > 25%
    improvement from Baseline to endpoint in YGTSS TTS OR a CGI-TS
    change score of 1 [very much improved] or 2 [much improved] at
    endpoint)
    -Treatment discontinuation rates
    -Cambio desde los valores iniciales hasta los valores finales en la escala en la puntuación total de tics (TTS, por sus siglas en inglés) de la escala YGTSS.
    -Cambio medio en la puntuación de la escala CGI-TS al final (cambio de puntuación obtenido por la evaluación con la escala de mejoría CGI-TS).
    -Cambio desde los valores iniciales hasta los valores finales en la puntuación de la gravedad en la escala CGI-TS.
    -Cambio medio desde los valores iniciales hasta los valores finales en la puntuación total de la escala YGTSS.
    -Tasas de respuesta (la respuesta clínica se definirá como una mejora > 25% desde la visita inicial hasta el final en la puntuación total de tics (TTS, por sus siglas en inglés) de la escala YGTSS O BIEN un cambio en la puntuación en la escala CGI-TS de 1 [mejoró bastante] o 2 [mejoró mucho] al final).
    -Tasas de suspensión del tratamiento.
    E.5.2.1Timepoint(s) of evaluation of this end point
    52 weeks
    52 semanas
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Belgium
    Bulgaria
    Canada
    Finland
    Germany
    Hungary
    Italy
    Mexico
    Netherlands
    Peru
    Poland
    Romania
    Spain
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Date of Contact or the Date of Final Contact Attempt from the Post-treatment Follow-up eCRF page for the last subject completing or withdrawing from the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days22
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 96
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 58
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 38
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 46
    F.4.2.2In the whole clinical trial 96
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no post trial treatment plans. All subjects (completers and subjects who receive at least 1 dose of trial drug and discontinue the trial for any reason) will be followed up for safety reasons 30 days (+ or - 3 days) after the last trial visit. Follow-up will consist of telephone contact to assess any AEs experienced since the last trial visit and information on ongoing AEs and serious AEs (SAEs) and recording of concomitant medications.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-03-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-02-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA